They found novel somatic mutations in the MAPK1 gene (8%), HLA-B gene (9%), EP300 (16%), FBXW7 (15%), NFE2L2 (4%), and ERBB2 (6%) of 79 squamous carcinomas, and ELF3 (13%) and CBFB (8%) mutations in 24 adenocarcinomas. This evidence concerns the gene CBFB and squamous cell carcinoma.